A large Phase III study found that shark cartilage extract AE-941 has no benefit when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer. The study did not meet its primary endpoint: survival, and the researchers cast major skepticism on the efficacy of shark cartilage products.
A new study by Duke University Comprehensive Cancer Center researchers shows that E Tables may be useful in collecting patient history data and conducting clinical research. Patients report being satisfied with the tablets and finding them comparable to paper forms in terms of data quality.
A recent Phase II study evaluating the addition of GEMZAR to standard chemotherapy regimens showed promising results in treating stage II-III breast cancer. The treatment regimen demonstrated a high pathologic complete response rate, with additional benefits for HER-2 positive patients who received trastuzumab. These findings support t...
A study by Dana-Farber Cancer Institute found that exercising lower insulin levels in breast cancer survivors, potentially improving prognosis. The research suggests exercise may also improve insulin sensitivity and reduce hip circumference, leading to improved health outcomes.
Research from Dana-Farber Cancer Institute reveals that Black Americans are less certain about lung cancer prevention recommendations and more fearful of symptoms evaluation, potentially delaying treatment. This fatalism may contribute to Black patients being diagnosed with advanced stages of the disease.
Recent studies conducted at Mayo Clinic have found that MRI is superior to mammography in detecting additional tumors in the same breast and identifying new tumors in the healthy breast. The technology has also revealed distinct patterns between ipsilateral and contralateral tumors, guiding its use.
A new study published by Duke University Comprehensive Cancer Center found that patients with chronic illnesses like diabetes or heart disease are no more likely to receive an early cancer diagnosis due to frequent healthcare interactions. Screening is still crucial regardless of medical management.
Pazopanib, an oral angiogenesis inhibitor, demonstrated a 27% week 12 response rate and 73% total disease control rate in patients with advanced renal cell carcinoma. The study showed clear clinical activity in treating this type of cancer.
A pilot study by Mayo Clinic researchers found that high-dose American ginseng improves fatigue and vitality in cancer patients. Patients receiving the highest dose showed significant improvements in overall energy levels, mental, physical, spiritual, and emotional well-being.
Researchers found that radium-223 significantly reduced levels of bone alkaline phosphatase, a marker for HRPC progression, by 66% and prolonged median survival time by 41 weeks. However, treatment had no significant effect on skeletal-related events.
Researchers delivered gene therapy containing nerve growth factors to rats with erectile dysfunction, resulting in significant recovery of intracavernous pressure and systemic arterial pressure. The study suggests a long-term treatment option for erectile dysfunction without chronic drug administration.
Preliminary results of a Phase II trial show favorable outcomes for patients with recurrent epithelial ovarian cancer treated with VEGF Trap. After one month, 85% of participants showed stable disease, while 41% continued to have stable disease after fourteen weeks.
A study reveals that genetic differences in Japanese and US patients with non-small cell lung cancer affect how well they respond to chemotherapy drugs like paclitaxel and carboplatin. The research found that specific gene variations, such as CYP3A4 and ERCC2, influence treatment outcomes.
A new study developed a simple marker that allows urologists to identify men at risk for high-grade prostate cancer, even after a negative initial biopsy. This finding could reduce overtreatment and unnecessary biopsies while improving patient outcomes.
A study of 519 patients found no benefit in overall survival from pre-operative chemotherapy for nonsmall cell lung cancer. Neo-adjuvant therapy did result in tumor down-staging and improved response rates, but its use should be targeted towards specific patient subgroups.
A new genomic test can identify specific patterns among thousands of genes to determine the precise pathways that led to lung cancer. Researchers found that tumors with defects in certain pathways responded well to targeted therapy, offering a potential alternative to traditional chemotherapy.
Pazopanib demonstrated high response rates of 27% and stable disease in 46% of patients with advanced renal cell carcinoma (RCC). In ovarian cancer, pazopanib showed biological activity in 41% of evaluable patients. These findings support further investigations into pazopanib's therapeutic potential.
Researchers at Duke University Medical Center found that flaxseed supplementation significantly slows prostate tumor growth in men scheduled for surgery. Flaxseed's omega-3 fatty acids and lignans appear to play a crucial role in halting cancer cell proliferation.
A Phase III study suggests ALIMTA-carboplatin may deliver less toxicity than GEMZAR-carboplatin, offering comparable quality-of-life benefits and survival data. The combination also appears to benefit from a lower toxicity profile.
A Phase II clinical trial at M.D. Anderson Cancer Center found dasatinib achieves complete cytogenetic response in 77-95% of newly diagnosed CML patients, compared to historical data on imatinib. The rapid response rate suggests dasatinib may be more effective as a first-line treatment for CML.
A multicenter Phase II study of enzastaurin as a second- or third-line treatment for NSCLC found a median progression-free survival of 1.9 months and an overall survival rate of 46.3% at 12 months. The most common toxicity was fatigue.
Researchers found that patients with higher levels of protein S-100 in their serum samples had a greater likelihood of melanoma returning after treatment. The study identified S-100 as a potential biomarker for predicting disease recurrence and stratifying patients into those more or less likely to relapse.
A predominantly Western diet high in red meat, fatty foods, refined grains, and desserts is associated with faster cancer recurrence and lower overall survival rate in stage III colon cancer patients. In contrast, a prudent diet rich in fruits, vegetables, poultry, and fish does not significantly influence cancer recurrence or mortality.
The OHSU Cancer Institute study found that sipuleucel-T vaccine slowed the rate of rise of serum PSA in exploratory analyses, but did not significantly delay cancer progression. The treatment also showed a favorable safety profile with common side effects like fatigue and chills.